Page 33 - Gates-AnnualReport-2019
P. 33

With new solutions in mind, the Gates Grubstake Fund is an initiative of the Gates Frontiers Fund and a key component of the Gates Center for Regenerative Medicine’s commercialization strategy for projects and teams affiliated with the Gates Center. Through a process overseen by the Gates Center with significant support from CU Innovations, Grubstake Fund investment decisions regarding three to four annual awards of up to $350,000 are made on a competitive basis by a Scientific Investment Advisory Committee comprised of subject matter experts and institutional investors with a focus on biotechnology:
• Mark Brunvand, M.D., Field Medical Director, CAR T-cells, Bristol-Myers Squibb
• William Hiatt, M.D., Professor, Division of Cardiology, University of Colorado Anschutz Medical Campus; Past President
and now Chief Science Officer, CPC Clinical Research
• Ryan Kirkpatrick, Partner, Colorado Impact Fund
• David L. Lacey M.D., Biopharmaceutical Consultant, former SVP, Head of Research, Amgen
• Mark Lupa, Ph.D., Principal, High Country Ventures
• Kimberly Muller, J.D., Managing Director, CU Innovations, University of Colorado Anschutz Medical Campus
• Mark Petrash, Ph.D., Professor and Vice Chair, Department of Ophthalmology, Associate Director, Gates Center for
Regenerative Medicine, University of Colorado Anschutz Medical Campus
• Matthew Seefeldt, Ph.D., Director of Cell Therapy, Gates Biomanufacturing Facility
• Geoff “Duffy” Solich, Executive Vice President, E & P Resources LLC; member, Gates Center Advisory Board
• Ann Sperling, Senior Director, Trammell Crow Company; member, Gates Advisory Board
• Robert Traver, J.D., Patent Attorney, Sheridan Ross
Terry Fry, M.D.
Optimized manufacturing of CD19xCD22 CAR expressing T cells for the clinic
Refractory cancers are an increasing cause of early death in adults and children. Recent breakthroughs in cell based immunotherapeutic treatments (primarily CAR-T cell therapy) are changing that rapidly, with hundreds of trials ongoing in the U.S. and around the world. Although some patients may be cured with current monovalent CAR-T cell therapy (that targets only CD19), relapses shorten remissions in a majority of patients. Dr. Terry Fry and his team are developing a next generation bicistronic CAR-T cell therapy (that targets both
CD19 and CD22) designed to prolong remissions in patients, improving patient well-being and decreasing healthcare costs. The Grubstake Award will allow them to develop the manufacturing process at the Gates Biomanufacturing Facility.
 Gates Center for Regenerative Medicine 33

   31   32   33   34   35